This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Porfiromycin
Accession Number
DB06478
Type
Small Molecule
Groups
Investigational
Description

Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-56410 / U-14,743 / U-14743
International/Other Brands
Promycin
Categories
UNII
H1WK901OA6
CAS number
801-52-5
Weight
Average: 348.359
Monoisotopic: 348.14336976
Chemical Formula
C16H20N4O5
InChI Key
HRHKSTOGXBBQCB-VFWICMBZSA-N
InChI
InChI=1S/C16H20N4O5/c1-6-10(17)13(22)9-7(5-25-15(18)23)16(24-3)14-8(19(14)2)4-20(16)11(9)12(6)21/h7-8,14H,4-5,17H2,1-3H3,(H2,18,23)/t7-,8+,14+,16-,19?/m1/s1
IUPAC Name
[(4S,6S,7R,8S)-11-amino-7-methoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate
SMILES
CO[C@]12[C@@H]3[C@H](CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O)N3C

Pharmacology

Indication

Investigated for use/treatment in head and neck cancer.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Porfiromycin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Porfiromycin.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Porfiromycin.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Porfiromycin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Porfiromycin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Porfiromycin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Porfiromycin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Porfiromycin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Porfiromycin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Porfiromycin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Porfiromycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Porfiromycin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Porfiromycin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Porfiromycin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Porfiromycin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Porfiromycin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Porfiromycin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Porfiromycin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Porfiromycin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Porfiromycin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Porfiromycin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
12565
ChEMBL
CHEMBL521078

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentNeoplasms, Head and Neck1
3CompletedTreatmentCarcinoma of Unknown Primary / Head and Neck Carcinoma1
3CompletedTreatmentHead and Neck Carcinoma1
3TerminatedTreatmentNeoplasms, Head and Neck1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility23.3 mg/mLALOGPS
logP0ALOGPS
logP-2.5ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.9ChemAxon
pKa (Strongest Basic)4.15ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area127.96 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.56 m3·mol-1ChemAxon
Polarizability34.81 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as mitomycins. These are polycyclic compounds with a structure based on an aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolequinones
Direct Parent
Mitomycins
Alternative Parents
Indoles / Quinones / Pyrrolizines / N-methylpiperazines / Vinylogous amides / Carbamate esters / Pyrrolines / Pyrrolidines / Trialkylamines / Organic carbonic acids and derivatives
show 7 more
Substituents
Mitomycin / Indole / Pyrrolizine / Quinone / N-methylpiperazine / N-alkylpiperazine / 1,4-diazinane / Piperazine / Pyrrolidine / Pyrroline
show 21 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Pan SS, Iracki T: Metabolites and DNA adduct formation from flavoenzyme-activated porfiromycin. Mol Pharmacol. 1988 Aug;34(2):223-8. [PubMed:3412325]

Drug created on March 19, 2008 10:34 / Updated on July 02, 2018 18:33